This is a US news story, published by Ars Technica, that relates primarily to Novo Nordisk news.
For more US news, you can click here:
more US newsFor more Novo Nordisk news, you can click here:
more Novo Nordisk newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Ars Technica, you can click here:
more news from Ars TechnicaOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Novo Nordisk. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest current pricing news, Sanders news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
CEO Lars JørgensenArs Technica
•81% Informative
Novo Nordisk CEO Lars Jørgensen will testify before lawmakers in September .
Sen. Bernie Sanders has been trying to pressure the company to lower prices of its diabetes and weight-loss drugs in the US .
Sanders has canceled a vote on whether to subpoena the company over its prices.
VR Score
81
Informative language
79
Neutral language
62
Article tone
formal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Affiliate links
no affiliate links